about
Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent responseXanthurenic Acid Activates mGlu2/3 Metabotropic Glutamate Receptors and is a Potential Trait Marker for SchizophreniaSystematic Review of Clozapine Cardiotoxicity.Anti-CGRP monoclonal antibodies in migraine: current perspectives.Activation of mGlu2/3 metabotropic glutamate receptors negatively regulates the stimulation of inositol phospholipid hydrolysis mediated by 5-hydroxytryptamine2A serotonin receptors in the frontal cortex of living mice.OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study.A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience.Altered serum levels of kynurenine metabolites in patients affected by cluster headacheImpact of migraine on fibromyalgia symptoms.Altered kynurenine pathway metabolites in serum of chronic migraine patientsPharmacological strategies against glucocorticoid-mediated brain damage during chronic disorders.The Prevention and Treatment of Delirium in Elderly Patients Following Hip Fracture Surgery.Fathoming the kynurenine pathway in migraine: why understanding the enzymatic cascades is still critically important.O066. Kynurenine pathway metabolites in cluster headache.Choosing the safest acute therapy during chronic migraine prophylactic treatment: pharmacokinetic and pharmacodynamic considerations.Lasmiditan for the treatment of migraine.Acute, transitional and long-term cluster headache treatment: pharmacokinetic issues.Chronic migraine treatment: from OnabotulinumtoxinA onwards.Cinnabarinic acid and xanthurenic acid: Two kynurenine metabolites that interact with metabotropic glutamate receptors.Increased serum Dickkopf-1 levels in drug-abusing psychotic patients.The Italian version of the 92-item Prodromal Questionnaire: Concurrent validity with the SIPS and factor analysis in a sample of 258 outpatients aged 11-36years.LC-MS/MS simultaneous analysis of allopregnanolone, epiallopregnanolone, pregnanolone, dehydroepiandrosterone and dehydroepiandrosterone 3-sulfate in human plasma.Impairment in Social Functioning differentiates youth meeting Ultra-High Risk for psychosis criteria from other mental health help-seekers: A validation of the Italian version of the Global Functioning: Social and Global Functioning: Role scales.Antidepressant effectiveness of deep Transcranial Magnetic Stimulation (dTMS) in patients with Major Depressive Disorder (MDD) with or without Alcohol Use Disorders (AUDs): a 6-month, open label, follow-up study.Antipsychotic treatment and the Rorschach Perceptual Thinking Index (PTI) in psychotic disorder patients: Effects of treatment.Increased Total Urinary Cortisol (tUC) and Serum Brain-derived Neurotrophic Factor (BDNF) Ratio in Alzheimer Disease (AD)-affected Patients.Electroconvulsive therapy improves clinical manifestations of treatment-resistant depression without changing serum BDNF levels.Impairment of left ventricular function early in treatment with clozapine: a preliminary study.Features preceding diagnosis of bipolar versus major depressive disorders.The presence of depressive symptoms in comorbidity with Alzheimer's disease does not influence changes in serum brain-derived neurotrophic factor levels in older patients.Validation of the Italian version of interpersonal sensitivity measure (IPSM) in adolescents and young adults.Effects of escitalopram on serum BDNF levels in elderly patients with depression: a preliminary report.Executive functions in obsessive-compulsive disorder: An activation likelihood estimate meta-analysis of fMRI studies.Interpersonal sensitivity and functioning impairment in youth at ultra-high risk for psychosis.Self-reported attenuated psychotic-like experiences in help-seeking adolescents and their association with age, functioning and psychopathology.Neurocognition in schizophrenia: from prodrome to multi-episode illness.Basic symptoms and psychotic symptoms: their relationships in the at risk mental states, first episode and multi-episode schizophrenia.Neurocognition, psychopathology, and subjective disturbances in schizophrenia: a comparison between short-term and remitted patients.A Critical Evaluation on MOH Current Treatments.Psychiatric Comorbidity in Migraine and Chronic Headache
P50
Q28074159-D8F87409-8A50-4B81-9F30-9539768F288BQ28270694-764D3426-3B26-42C1-9C60-E3E593A7919EQ30250192-85BB9A85-E717-4E2E-9902-0412232A625DQ34531880-EFF2970D-6EE9-4116-9FCC-79C7C6EA3CC5Q34980799-A170491B-3E31-4942-B683-01D8890F2BCFQ36415380-58515182-7A10-4F8B-9BB6-B6A1B041422DQ36484239-ECA179E4-F11E-4E74-AE3E-E6DE076D43FEQ36712255-3AE27F6A-C3F4-4D79-82AF-39340E28132EQ36717622-6B4CE51F-DB19-43DC-A641-7ABD5DF2E961Q36853404-466352BC-B1BD-4F0F-A9A6-EEDF6D837E3AQ37915583-CF0A0E8E-496D-45CA-9FA9-FF1115EA88EEQ38357731-28F69A77-5261-4EA9-B377-6DC23698C4F9Q38364549-B3AB7F98-CD8E-4823-BE16-9AB927C3B093Q38553382-A2E9045B-EC74-4BEE-A441-D24F57ECBF39Q38734042-016EEFC7-40B0-484A-A6B7-61E22C83874FQ38771819-680B0D43-1917-4A15-AD3A-735401D73A64Q38866983-10980D30-BA00-4EB4-824A-5F8CF70DBE0CQ38866988-C94634B0-C354-4D23-8625-68E6CE1FE05DQ38876214-921F8C0C-9CD0-4A7C-A5FC-65CAAC5B310AQ44620574-8381BA1C-FBF7-4B77-9EED-868DCEAF9289Q46843951-3025E0D2-2127-4EF1-A060-C86A1FA7AB19Q47329923-C2229A7D-825E-4333-826A-9F2F2782D143Q47747640-FB0402DA-4D0E-4A12-96C4-B25D8079CE44Q47775607-23E67135-2EE6-4629-AF42-30EFCB8292C1Q47791575-E96EB6DE-68FE-434B-AC49-62AA5ADFDD36Q48020851-FF0F4F9F-0FAF-4F78-BCED-60521D300450Q48084657-CEF13058-3776-46A0-BFE8-9A02A12519F7Q48141442-21C52184-2228-415F-BCA9-0BA6CCCAAFB4Q48161109-96DAE811-9184-4B12-9E96-CE7998ADE770Q48340134-F12AD3B1-7686-49B4-A93B-297836FED74AQ48368720-CBF9E9A5-8688-462B-9D80-1A693A2E709DQ48369283-ED98020B-3BC2-4602-BF66-90C3B3D0CF6FQ50551342-E014887A-63D9-4635-975E-E81A0CE7306FQ50596157-2CF11309-C3F5-4532-8B16-A24A16CD5730Q50608874-6E0DBB35-77E5-4174-A6DC-D382E8A41443Q50626266-BB65951F-A52A-40D9-9DD7-53E02841C674Q50658782-E0160E11-6201-4F3F-80FA-816BA27070F7Q50960860-E74EA778-F434-461E-8058-901E3FF56D38Q54795534-7AA96DCF-CCD4-40B5-AA3C-226375866CDFQ60445898-FF807C49-398C-42CA-AE95-CBCE5551BBA7
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-6084-8578
@en
name
M Curto
@nl
Martina Curto
@en
Martina Curto
@es
type
label
M Curto
@nl
Martina Curto
@en
Martina Curto
@es
altLabel
M Curto
@en
prefLabel
M Curto
@nl
Martina Curto
@en
Martina Curto
@es
P106
P1153
34970932600
P21
P31
P496
0000-0002-6084-8578